Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Bausch & Lomb's Enterprise Value is C$12,072 Mil.
Bausch & Lomb's EBIT for the trailing twelve months (TTM) ended in Mar. 2025 was C$94 Mil. Therefore, Bausch & Lomb's EV-to-EBIT ratio for today is 127.83.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Bausch & Lomb's Enterprise Value is C$12,072 Mil.
Bausch & Lomb's EBITDA for the trailing twelve months (TTM) ended in Mar. 2025 was C$697 Mil. Therefore, Bausch & Lomb's EV-to-EBITDA ratio for today is 17.31.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Bausch & Lomb's Enterprise Value is C$12,072 Mil.
Bausch & Lomb's Revenue for the trailing twelve months (TTM) ended in Mar. 2025 was C$6,743 Mil. Therefore, Bausch & Lomb's EV-to-Revenue ratio for today is 1.79.
EV-to-FCF is calculated as Enterprise Value divided by its Free Cash Flow. As of today, Bausch & Lomb's Enterprise Value is C$12,072 Mil.
Bausch & Lomb's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2025 was C$-244 Mil. Therefore, Bausch & Lomb's EV-to-FCF ratio for today is -49.41.
Bausch & Lomb Enterprise Value Historical Data
The historical data trend for Bausch & Lomb's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Bausch & Lomb's Enterprise Value
For the Medical Instruments & Supplies subindustry, Bausch & Lomb's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bausch & Lomb's Enterprise Value Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Bausch & Lomb's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Bausch & Lomb's Enterprise Value falls into.
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Bausch & Lomb's Enterprise Value for the fiscal year that ended in Dec. 2024 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bausch & Lomb (TSX:BLCO) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Bausch & Lomb's current Enterprise Value is C$12,072 Mil.
Bausch & Lomb's EBIT for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was C$94 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Bausch & Lomb's current Enterprise Value is C$12,072 Mil.
Bausch & Lomb's EBITDA for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was C$697 Mil.
Bausch & Lomb's current Enterprise Value is C$12,072 Mil.
Bausch & Lomb's Revenue for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was C$6,743 Mil.
Bausch & Lomb's current Enterprise Value is C$12,072 Mil.
Bausch & Lomb's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-244 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bausch & Lomb Enterprise Value Related Terms
Thank you for viewing the detailed overview of Bausch & Lomb's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
TSX:BLCO has been successfully added to your 